gptkbp:instance_of
|
gptkb:biotechnology
|
gptkbp:accessories
|
gptkb:European_Commission
|
gptkbp:acquisition
|
Pfizer partnership
|
gptkbp:awards
|
European Inventor Award 2021
|
gptkbp:ceo
|
gptkb:Ozlem_Tureci
gptkb:Uğur_Şahin
|
gptkbp:clinical_trial
|
gptkb:Germany
Phase 1
Phase 2
Phase 3
44,000
|
gptkbp:collaborates_with
|
gptkb:Fosun_Pharma
|
gptkbp:collaboration
|
gptkb:Sanofi
gptkb:Moderna
|
gptkbp:collaborations
|
gptkb:Harvard_University
gptkb:National_Institutes_of_Health
|
gptkbp:community_impact
|
gptkb:COVID-19_pandemic
|
gptkbp:focus
|
m RNA technology
|
gptkbp:founded
|
gptkb:2008
|
gptkbp:founder
|
gptkb:Uğur_Şahin
|
gptkbp:funding
|
$2 billion (2021)
|
gptkbp:headquarters
|
gptkb:Mainz,_Germany
|
https://www.w3.org/2000/01/rdf-schema#label
|
Bio NTech RNA Pharmaceuticals
|
gptkbp:invention
|
m RNA technology patents
|
gptkbp:investment
|
$1.5 billion (2020)
|
gptkbp:is_a_platform_for
|
m RNA-based therapeutics
|
gptkbp:is_vulnerable_to
|
gptkb:BNT162b2
gptkb:significant
gptkb:FDA
gptkb:vaccine
gptkb:Comirnaty
95%
December 2020
global
ongoing
monitored
intramuscular injection
less than a year
-70° C
|
gptkbp:number_of_employees
|
over 1,000
|
gptkbp:partnership
|
gptkb:Pfizer
gptkb:Cure_Vac
|
gptkbp:product
|
gptkb:BNT162b2
|
gptkbp:publications
|
gptkb:Nature
|
gptkbp:research_areas
|
gptkb:immunotherapy
infectious diseases
|
gptkbp:research_focus
|
cancer vaccines
|
gptkbp:revenue
|
$18.9 billion (2021)
|
gptkbp:stock_exchange
|
gptkb:NASDAQ
|
gptkbp:stock_symbol
|
gptkb:BNTX
|
gptkbp:type_of_vaccine
|
gptkb:vaccine
|
gptkbp:vaccine_approval_authority
|
gptkb:EMA
|
gptkbp:vaccine_clinical_trial
|
successful
|
gptkbp:vaccine_distribution_partnership
|
gptkb:UPS
|
gptkbp:vaccine_doses
|
2 doses
|
gptkbp:vaccine_efficacy_rate
|
high
|
gptkbp:vaccine_production
|
Germany and Belgium
|
gptkbp:vaccine_storage_temperature
|
-80° C to -60° C
|
gptkbp:vaccine_target
|
gptkb:SARS-Co_V-2
|
gptkbp:bfsParent
|
gptkb:Bio_NTech
|
gptkbp:bfsLayer
|
5
|